Gastrin stimulates growth of colon cancer

Gastrin is trophic for normal gastric and colonic mucosa. We examined the potential trophic effects of chronic gastrin administration on the growth of mouse colon adenocarcinoma (MC-26). Thirty-three mice bearing transplantable MC-26 colon cancers were treated with varying doses (125, 250, or 500 micrograms/kg/day) of pentagastrin. Significant increases in tumor weight and DNA content were observed. Fundic mucosal weight and DNA content in these mice showed a dose-related trophic response. The weight of control fundic mucosa was 10 mg and rose to 20, 45, and 65 mg with increasing doses of gastrin. The DNA content of control fundic mucosa was 155 micrograms and rose to 220, 340, and 480 micrograms as the dose of gastrin was increased. Pentagastrin stimulated growth of the MC-26 colon cancer, but the threshold for gastrin-stimulated tumor growth was different from that of normal mucosal growth. The hyperplastic response of the fundic mucosa was increased by increasing gastrin doses; whereas, colon cancer hyperplasia was maximal at the lowest dose tested (125 micrograms/kg/day) and did not increase further with increasing doses of hormone. Mice bearing gastrin-stimulated tumors died at a significantly greater rate than did mice with untreated tumors (80% of control mice and none of the treated mice were alive at day 55). The effects of gastrin treatment on the growth of MC-26 colon cancer persist after treatment is discontinued; mice with tumors that were treated with gastrin for either 7 or 14 days and in which the treatment was stopped were all dead by 35 or 28 days, respectively, after the end of treatment.     

Gastrin-mediated effects of omeprazole on rat colon mucosa.

BACKGROUND: Omeprazole increases circulating gastrin levels, which in turn may affect the growth and differentiation of colon mucosa. Chloride transport mechanisms in normal colon were analyzed as markers for possible trophic actions of endogenous hypergastrinemia. METHODS: Four groups of Fischer rats were studied for 10 days. Group 1 (baseline) received no treatment. Group 2 received omeprazole only. Group 3 received omeprazole plus vehicle. Group 4 received omeprazole plus CCK-B gastrin receptor antagonist (GRA) L740,093 in vehicle. On day 10 serum gastrin was assayed. Colon mucosa was analyzed for protein and DNA content. Semiquantitative Northern analysis measured levels of messenger RNA (mRNA) encoding for key Cl- transporters: Na-K-Cl cotransporter (Cl- secretion in crypts), Cl-/HCO3- exchanger (Cl- absorption in villi), and Na/K adenosine triphosphatase (not directly involved in Cl- transport). RESULTS: Omeprazole increased gastrin levels, which were not altered by vehicle or GRA. Omeprazole increased protein, DNA, and Na/K adenosine triphosphatase mRNA levels, with no effect by GRA. In contrast, omeprazole decreased Na-K-Cl and Cl-/HCO3- mRNA levels, effects that were partly reversed by GRA. CONCLUSIONS: Omeprazole augments growth index values of colon mucosa independent of serum gastrin. Against a background of omeprazole-induced achlorhydria hypergastrinemia appears to influence differentiation rather than growth of normal colon mucosa.     

电穿孔化疗对结肠癌裸鼠移植瘤模型的作用研究

目的:观察电穿孔技术结合博莱霉素化疗对结肠癌裸鼠移植瘤的抗肿瘤效果,为本疗法的临床应用提供实验依据。方法:于裸鼠左前肢皮下接种人结肠癌LoVo单细胞悬液,3周后成功建立结肠癌裸鼠皮下移植瘤模型40只,随机将其分为电穿孔化疗(B E )组、单纯化疗(B E-)组、单纯电穿孔(B-E )组和阴性对照(B-E-)组,每组10只。动态观察肿瘤大小,治疗第7天处死小鼠并取出皮下肿瘤称重,。并观察其组织学改变。结果:B E 组裸鼠移植瘤体积较其他各组明显缩小(P<0.01),该组1只裸鼠的移植瘤呈完全缓解,部分缓解7只;B-E 和B E-组内各有1只部分缓解,而B-E-组中无一有效。B E 组有效率与其余各组的差别有统计学意义(P<0.01)。组织学观察也显示B E 组的移植瘤内大片肿瘤细胞坏死、血管损伤和炎细胞浸润。结论:电穿孔化疗可显著增强结肠癌裸鼠皮下移植瘤对化疗的敏感性,疗效明显,有可能成为结直肠癌治疗的一种新方法。     

Functional paraganglioma with tumor thrombus in the inferior vena cava,first case report

Pheochromocytoma (PHEO) is a rare neuroendocrine that tumor originated from the adrenal medulla that secrets catecholamines. Tumors from extra-adrenal chromaffin tissues are called extra-adrenal PHEO or paraganglioma (PGL). To our knowledge, adrenal PHEO and subclinical PGL with inferior vena cava (IVC) invasion had been sporadically reported, while functional PGL with IVC tumor thrombus has not been publicly reported yet. Perioperative management of those diseases is less well established because of their multidisciplinary nature and rarity. We herein present a case of primary malignant PGL with IVC invasion. A 16-year-old female patient with a history of severe paroxysmal hypertension was admitted to Peking Union Medical College Hospital on suspicion of retroperitoneal mass. In-house diagnostic work-up revealed a malignant PGL with IVC invasion, inferior mesenteric artery encasement and, aorta engagement. Multi-disciplinary discussions were held and careful preoperative preparation plans were made. After everything was ready, the functional PGL and tumor thrombus were completely resected, then a reconstruction of IVC was performed. The patient was discharged on postoperative day 14 and all her clinical symptoms disappeared afterward. No evidence of tumor residual or metastasis was found in the subsequent six months of follow-up. Gene tests were made for her and her family. Albeit its rarity, functional PGL with IVC invasion is not unresectable, a multi-disciplinary task force should be established to settle down every detail. We recommended 3-dimensional imaging reconstruction for gaining a better anatomic understanding. Literature reviews showed that complete resection is the premise of a good prognosis. In particular cases, complementary or alternative therapy like chemotherapy and ¹³¹I-metaiodobenzylguanidine might help, family hereditary genetic tests are advised as well.     

Higher colon cancer tumor proliferative index and lower tumor cell death rate in mice undergoing laparotomy versus insufflation

BACKGROUND: Our laboratory has previously shown that tumors are established more easily and grow larger after laparotomy than after laparoscopy. To characterize these differences in tumor growth further, the tumor cell death rates and tumor proliferation rates were compared in vivo after full sham laparotomy versus carbon dioxide (CO2) insufflation. METHODS: Female Balb/C mice (n = 36) were inoculated intradermally in the dorsal skin with 106 C-26 colon adenocarcinoma cells in 0.1 ml of culture media no more than 1 h before interventions. The mice then were randomized to one of three groups: anesthesia control, CO2 insufflation, or sham laparotomy. The anesthesia control group underwent no procedure. The insufflation group underwent CO2 pneumoperitoneum (4-6 mmHg) for 20 min via a 20-gauge angiocatheter. The laparotomy group underwent a midline incision from xiphoid to pubis, which was closed after 20 min. Tumors were excised from half the mice in each group on postoperative day 7, and from the remaining mice on postoperative day 14. Sections of tumors were made then stained separately for free 3? hydroxyl ends of genomic deoxyribonucleic acid (DNA) using fluorescein-deoxyunidine triphosphate (dUTP), and immunohistochemically for proliferating cell nuclear antigen (PCNA). Apoptosis was measured by quantitating DNA strand breaks in individual cells using fluorescence microscopy. Fluorescein-positive cells in five random high-power fields (x200) were counted in a blinded fashion. The proliferative index of each tumor was determined by averaging PCNA positive cells in five high-power fields (x450) counted in a blinded fashion with the aid of an optical grid. RESULTS: On postoperative day 7, there was no significant difference in the proliferative index or apoptotic rates among the three groups. On postoperative day 14, the proliferative index in the laparotomy group was significantly higher than in either the insufflation or control group (p < 0.001). The proliferative index in the insufflation group also was significantly higher than in the control group (p < 0.05). Inverse differences in apoptotic rates were found. The apoptotic rate in the laparotomy group was significantly lower than in either the insufflation (p < 0.05) or control group (p < 0.001). The apoptotic rate in the insufflation group was significantly lower than in the control group (p < 0.001). CONCLUSIONS: We have demonstrated that there is a significantly higher rate of tumor cell proliferation and a significantly lower rate of tumor cell death with the C-26 colon adenocarcinoma tumor line after laparotomy than after insufflation or anesthesia alone on post-operative day 14. The mechanisms of these phenomena are unclear. It appears that certain factors postoperatively stimulate tumors to proliferate at a higher rate, causing tumor cells to die at a lower rate in the laparotomy group than in the insufflation group.     

TNP-470对裸鼠体内人结肠癌细胞增殖和凋亡的影响

目的 研究TNP-470对裸鼠体内人结肠癌细胞增殖和凋亡的影响。方法 将16只人结肠癌皮下移植瘤裸鼠随机分成实验组和对照组，实验组隔日予以TNP-47030mg/kg，皮下注射，对照组予以相同体积的生理盐水，4周后处死，应用免疫组织化学法（免疫组化）和图象分析技术检测肿瘤细胞中增殖细胞核抗原（PCNA）的表达，TdT介导的dUTP缺口末端标记（TUNEL）法检测肿瘤细胞的凋亡，透射电镜观察凋亡细胞的超微结构。结果 TNP-470明显抑制了肿瘤的生长，抑瘤率为45.53%。实验组肿瘤中PCNA的表达显低于对照组，凋亡指数上升，电镜下可见典型的细胞凋亡形态学变化。结论 TNP-470除了通过抗血管生成作用抑制肿瘤生长外，还可通过抑制LOVO细胞本身的增殖和诱导凋亡发挥抗肿瘤作用。     

循环中胰岛素样生长因子-Ⅰ水平调节结肠癌的生长和转移研究

目的　探讨血清中肝特异性胰岛素样生长因子 Ⅰ (IGF Ⅰ )水平在刺激小鼠结肠癌生长和转移中的作用。方法　我们实验中所用的肝脏特异性IGF Ⅰ基因缺失 (LID)小鼠 ,其循环中IGF Ⅰ水平仅为正常小鼠 (对照组小鼠 )的 2 5 %。将Colon 3 8腺癌组织块 (碎片 )植入LID和对照组小鼠的盲肠表面。总共 15 6只 5周龄的雄鼠 (其中 82只LID小鼠 ,74只对照鼠 )接受了肿瘤移植。小鼠被随机分成两组 :一组接受腹腔注射重组人IGF 1(rhIGF 1) ,每天 2次 ,共 6周 ,另一组接受生理盐水注射。结果　接受rhIGF Ⅰ注射组的LID和对照小鼠 ,血清IGF 1和IGFBP 3水平均升高。在生理盐水注射组中 ,对照鼠的盲肠肿瘤的发生率和肝脏转移率显著高于LID小鼠。和盐水注射组相比 ,腹腔注射rhIGF 1组中 ,LID和对照组小鼠均有显著的盲肠癌发生率和肝脏转移率。对照小鼠的肝脏转移结节数明显高于LID鼠。结肠癌组织VEGF的表达和血管的密度依赖于血液中IGF Ⅰ水平。结论　血液循环中IGF I水平在结肠癌发展和转移中起了重要作用。     

Insulin-like growth factor-binding protein 3 inhibits growth of experimental colocarcinoma

BACKGROUND: We have previously shown that an important cell growth regulatory protein, insulin-like growth factor-binding protein 3 (IGFBP-3) is depleted in peripheral blood after open--but not laparoscopic--surgery. We have also demonstrated that IGFBP-3 induces apoptosis of human colon cancer cells in vitro. We report here the effect of IGFBP-3 on the growth of colonic epithelial cells in vivo. METHODS: Two tumor models were used: chemically induced carcinogenesis with azoxymethane (AOM) and inoculation of syngeneic colon cancer cells. In AOM-induced carcinogenesis, wild type (WT) and IGFBP-3 transgenic (IGFBP-3-TG) CD1 mice were injected with AOM and the number of aberrant crypt foci (ACF) in the colon studied. In the syngeneic model, BALB/c mice were inoculated with CT26 cells. The control group received saline, while the test group was administered IGFBP-3 weekly. Tumor weight was assessed 2.5 weeks after establishment. RESULTS: The number of aberrant crypt foci was significantly lower in IGFBP-3 transgenic mice (1.3 +/- 1.1) compared to WT controls (6.8 +/- 6.0) (P < .001). Further, CT26 tumors were significantly smaller in BALB/c mice that received IGFBP-3 (0.364 +/- 0.165 g) than in WT controls (0.742 +/- 0.261 g) (P < .01). CONCLUSIONS: IGFBP-3 inhibits the development of colonic tumors in experimental models and may hold promise as an adjuvant therapy for patients with neoplasms.     

Biodistribution of radiolabeled monoclonal antibody after intraperitoneal administration in nude mice with hepatic metastasis from human colon cancer

The utility of the intraperitoneal (IP) administration of radiolabeled monoclonal antibody (mAb) for hepatic metastasis from human colon cancer was evaluated in congenital athymic mice. The intrasplenic injection of HT-29 LMM metastatic human colon cancer cell line reproducibly results in hepatic metastasis formation in nude mice. HT-29-15, a murine mAb of IgG1 class reactive with the HT-29 LMM cell line was labeled with iodine 125. One g/2 Ci of labeled HT-29-15 was injected intraperitoneally into mice with hepatic metastases, and additionally IP administration of the same dose of I-125 labeled HT-29-15 with increased volume and intravenous (IV) administration of dose quantity of HT-29-15 were performed. Blood samples were obtained at 1, 3, 5 hours, and the animals were sacrificed on days 1, 3, and 5. The per cent of injected dose per gram (%ID/g) of blood after IP administration of I-125 labeled HT-29-15 reached the same level of %ID/g after IV administration by 5 hours. The transfer from the peritoneal cavity to blood was delayed by increasing the volume injected. From day 1 to day 3, there was a progressive increase for hepatic metastasis/blood ratios of I-125 labeled HT-29-15 in each group. There was no difference in the hepatic metastasis/blood ratios among the three groups. IP administration of specific mAb, therefore, provides the same level of tumor uptake in hepatic metastasis from colorectal cancer, and would be advantageous in patients with both hepatic metastasis and peritoneal implants in which radioimmunodetection and radioimmunotherapy are appropriate.     

Electrochemotherapy significantly inhibits the growth of colon 26 tumors in mice

Electrochemotherapy is a novel antitumor treatment involving the systemic administration of bleomycin followed by the delivery of electrical pulses to the tumor. The present study investigates the effects of electrochemotherapy on the growth of colon 26 cells inoculated subcutaneously into the backs of BALB/c mice. The mice were divided into the following four experimental groups: 20 that received no further treatment after the inoculation of colon 26 cells (control group); 20 that received 500 μg of bleomycin intraperitoneally 7 and 9 days after the inoculation (BLM group); 20 that received electric pulses to the tumor 7 and 9 days after the inoculation (EP group); and 30 that received electrochemotherapy 7 and 9 days after the inoculation (ECT group). During 28 days of observation, no deaths due to tumor progression occurred in the ECT group, but there were 18 in the control group, 11 in the BLM group, and 18 in the EP group. While weight loss was observed in all groups, it was most remarkable in the control group. Tumor growth was significantly inhibited in the ECT group, compared to the other experimental groups (P<0.01). The results of this study demonstrated that electrochemotherapy significantly inhibited the growth of colon 26 tumors in mice, without causing any remarkable adverse effects.     

大肠癌病人肿瘤、癌旁粘膜中胃泌素、生长抑素及其分泌细胞的变化

通过观察大肠癌病人肿瘤和癌旁粘膜中胃泌素、生长抑素(SS)及其分泌细胞的变化,探讨病人体内胃泌素、SS变化的原因和意义。方法:采用放射免疫法(RIA)测定26例大肠癌病人肿瘤和癌旁粘膜中胃泌素、SS水平,并对其分泌细胞行免疫细胞化学观察。结果:肿瘤和癌旁粘膜中胃泌素含量极低且无胃泌素细胞存在。癌远旁粘膜(CDM,距肿瘤约5cm)SS水平低于癌近旁粘膜(CAM,距肿瘤0～2cm),高于肿瘤,两两相比相差均非常显著(P<0.01)。肿瘤中未见SS细胞;癌旁粘膜中SS细胞的形态、位置近于正常。CAM中SS水平与SS细胞数间呈非常显著之正相关(P<0.01)。结论:大肠癌与胃泌素、SS间存在着肯定的联系;CAM中SS上升的主要原因是粘膜中SS细胞数量增多并分泌大量的SS。这可能有助于延缓肿瘤的发生、发展,是机体对病灶的一种局部防御反应。     

胃癌非细胞毒性化疗的研究

目的 研究非细胞毒性化疗药物对胃癌生长的抑制作用及机制。方法 观察胃泌素受体（GR）拮抗剂对胃癌细胞株MKN45移植瘤生长的抑制作用；在测定34例胃癌患达GR折基础上，对GR阳性的胃癌患加用丙从胺（PGL），评坐其初步临床效果。结果 PGL组移植面积、重量、胃癌细胞DNA指数、DNA含量及S期细胞比例均低于对照组，PGL＋SST组更低；晚期胃体癌、胃底贲门癌易于表达GR；对14例GR阳性的胃癌患随访6－21月，对照组8例患中有2例死亡，PGL组6例均存活，结论 PLG能调控胃癌细胞株MKN45移植瘤的生长，有望能改善胃癌患的预后。     

Effect of local tumor removal and retained oncolysate on lung metastasis.

We reported earlier that oncolysate retained in the excision wound of a local tumor inhibits growth of remote tumor in the rat. We further studied this effect on pulmonary metastasis. C57BL/6 mice were given B16 melanoma F10 cells subcutaneously into the gluteal area (Day 0) and then intravenously on Day 10. On Day 14, mice were divided into four groups. Group 1 received a sham operation and no further treatment. Tumors were excised in the remaining mice. Group 2 received tumor excision alone. Groups 3 and 4 received injections of freeze-lysed tumor cells (TC) and lysate modified (PTC) with a hapten, L-phenylalanine mustard (PhM), respectively, into excision wounds. On Day 24, metastases were assessed by determining metastatic burden. Average diameters of excised tumors in repeated experiments ranged from 8.7 to 10.9 mm. In repeat experiments, pulmonary metastatic burden increased by as much as 52 to 181% in the tumor excised group (Group 2) in comparison with those receiving sham surgery (Group 1). However, metastatic burden was always reduced in Group 3. An even greater reduction was seen in Group 4. To study the possible involvement of macrophages, the production of prostaglandin-E2 (PGE2) and cytotoxicity of macrophages in these animals were examined. It was found that tumor excision enhanced PGE2 production by macrophages and suppressed their cytotoxicity, while TC inoculation prevented both of these changes. An even greater prevention was observed with PTC inoculation. These results indicate an association among macrophage cytotoxicity, PGE2 production of macrophages, and metastasis. In order to clarify the mechanism for these reactions, we did experiments using adherent splenic macrophages from the four groups of animals.(ABSTRACT TRUNCATED AT 250 WORDS)     

Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease.

BACKGROUND: The development of allograft vascular disease (AVD) may be related to altered expression of the fibrinolytic system. We determined the extent to which plasminogen activator inhibitor type 1 (PAI-1) expression in donor tissue influences intimal proliferation (IP) in a mouse model of AVD. METHODS: We utilized an end-to-end abdominal aortic transplant model in mice to investigate the development of IP in 3 groups of 6 recipients. Group A (negative control) utilized C57BL/6J strain mice as both donors and recipients. In Groups B (positive control) and C, C57BL/6J mice were vessel donors and CBA/J mice were recipients. Both groups received intraperitoneal anti-CD4 and anti-CD8 monoclonal antibodies (250 microg/week for 5 weeks). Group C recipients, however, were transplanted with vessels from C57BL/6J PAI-1 knockout mice. Animals were killed at 50 days. Transplanted aortas were removed and intimal areas calculated using morphometric analysis. RESULTS: Group A (mean intimal area 6421 +/- 8507 microm(2)) demonstrated very little IP in comparison to the other groups. IP was significantly higher in Group B (mean intimal area 56357 +/- 35629 microm(2)) than Group A (p = 0.008). Group C (mean intimal area 288195 +/- 123279 microm(2)) demonstrated significantly more intimal proliferation than either Groups A or B (vs B, p = 0.003; vs A, p < 0.001). The significance of these results is maintained if intimal thickness is measured as a stand-alone reference for the intimal response. CONCLUSIONS: Lack of PAI-1 expression in donor tissue greatly exaggerates the extent of IP after allogeneic transplantation and suggests that PAI-1 is important in limiting the early phase of AVD.     

Pentagastrin stimulation of human colon carcinoma

This study examines the trophic effects of pentagastrin administration on the growth of transplanted human colon carcinoma in mice. Three different human colon carcinomas were implanted into dorsal subcutaneous pouches of BALB-C athymic mice-tumor A, COLO 320 DM undifferentiated carcinoma; tumor B, WiDr epithelial carcinoma; and tumor C, mucus-producing signet-ring cell adenocarcinoma from a patient volunteer. Tumors grew for four to six weeks and then groups were randomly assigned to receive either saline injections or pentagastrin, 2.0 mg/kg three times a day for 14 days before harvest. Tumors were homogenized and analyzed for DNA, RNA, and protein contents. Each tumor type showed a different biochemical pattern of response to pentagastrin stimulation. The data confirm that pentagastrin is trophic to human colon carcinoma and suggest a possible clinical role for hormonal manipulation.     

Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer

No new chemotherapy agents have been developed recently that present hope for improving survival in patients with colon or rectal cancer. We undertook this study to investigate a new route of administering an old drug, 5-fluorouracil (5-FU). Sixty-six patients with advanced primary colon or rectal cancer were randomized to receive 12 cycles with increasing dosages of intravenous (IV) or intraperitoneal (IP) 5-FU; the mean follow-up time was three years. The maximal tolerable dose and objective adverse side effects were prospectively recorded. The mean daily dose of 5-FU given by the IV route was 904 mg; for the IP route it was 1361 mg (p2 less than 0.0001). Two of ten patients had recurrent peritoneal carcinomatosis when treated with IP 5-FU; ten of eleven patients treated with IV 5-FU developed peritoneal implants (p2 less than 0.003). The incidence of serious complications was the same, but hematologic toxicity and hepatic toxicity were significantly reduced in patients who received IP 5-FU. When 5-FU is delivered by the IP route, the tolerable dose of drug was markedly increased without an increase in adverse side effects. The natural history of surgically treated disease was changed by reducing the incidence of peritoneal carcinomatosis but time to relapse and survival was not improved. IP 5-FU may be recommended for investigation in patients with perforated colon cancer, peritoneal implants, or as one part of a multimodality treatment protocol for colorectal cancer. If 5-FU is given to patients with gastrointestinal malignancy, the IP route should be strongly considered.     

Leflunomid reduziert den Angiogenesescore und das Tumorwachstum subkutan implantierter Kolonkarzinomzellen im Mausmodell

BACKGROUND: The inhibition of tumorangiogenesis may be of importance in the additive treatment of various cancers. Leflunomide, a drug which has been approved in Germany for the therapy of rheumatoid arthritis, inhibits the activity of several growth factors in vitro. The aim of this study was to investigate the effects of the drug on tumor angiogenesis in a nude mouse model. MATERIALS AND METHODS: A total of 40 nude mice were injected with human colon carcinoma cells. Following randomization in 4 groups, therapy started on day five. Group 1 was treated daily with orally administered Leflunomide (35 mg/kg) dissolved in 1.5% Carboxymethylcellulose (CMC). Group 2 served as a control group and received 1 ml CMC orally per day. The animals of group 3 were treated daily with 35 mg Leflunomide/kg KG and 500 mg Uridine/kg dissolved in 1 ml Nacl 0.9% intraperitoneally. The 4th group again served as a control group and received only 500 mg Uridine/kg intraperitoneally each day. The main outcome criterion was the angiogenesis score (AS). In addition, the tumor volume and tumor weight were also assessed. The AS was determined by immunohistochemistry using an antibody against factor VIII related antigen. RESULTS: All animals tolerated the procedure well. In the Leflunomide and the Leflunomide/Uridine group the angiogenesis score (p < 0.01), the tumor volume (p < 0.01) and the tumor weight (p < 0.01) were lower compared to the respective control groups. CONCLUSION: The administration of Leflunomide leads to a significant reduction of tumor weight and tumor volume following subcutaneous injection of human colon carcinoma cells in a nude mouse model. This could be due to the reduction of tumor angiogenesis. Following further experimental and clinical studies, Leflunomide may come to play a role in the additive treatment of colonic carcinoma.     

Promotive effects of intravesical instillation of dimethylsulfoxide on bladder carcinogenesis in mice]

The effect of intravesical instillation of dimethylsulfoxide (DMSO) on bladder carcinogenesis was examined in mice. Experiment 1: Fifty-five female C3H/He mice were administered 0.05% N-butyl-N-(4-hydroxy-butyl) nitrosamine (BBN) in their drinking water for 8 weeks. In week 9 they were divided into two groups consisting of 25 mice each. Then, under nembutal anesthesia the first group was given weekly intravesical inatillations of 0.1 ml DMSO (minimum 99.0%) for 10 weeks. The second group received no treatment except anesthesia. All mice were killed 30 weeks after the begining of the experiment and their urinary bladder resected for histological examination. The incidence of bladder carcinoma was 93.7% (15.16) and 27.7% (6/22) in groups 1 and 2, respectively. These incidences differed significantly between the two groups. Experiment 2: One hundred and twenty female C3H/He mice were divided into two groups. The first group was given 0.05% BBN in their drinking water for 5 weeks and then tap water. The second group was not given BBN. In week 6, the first group was divided again into three groups (1, 2 and 3) consisting of 28, 26, and 27 mice, respectively. The second group was divided into groups 4 and 5 consisting of 21 and 18 mice, respectively. Under nembutar anaesthesia groups 1 and 4 received weekly intravesical instillation of 0.05 ml DMSO (minimum 99.0%) from weeks 6 to 13, Group 2 received weekly intravesical instillation of 0.05 ml distilled water from weeks 6 to 13. Groups 3 and 5 received no treatment except anesthesia.(ABSTRACT TRUNCATED AT 250 WORDS)     

抗血管生成药物Endostatin和SU6668联合氟尿嘧啶对结肠癌的影响

目的探讨血管生成抑制剂Endostatin和SU6668联合氟尿嘧啶（5-FU）对结肠癌生长和转移的抑制作用，并探讨其作用机制。方法建立人结肠癌裸鼠原位种植转移模型。将60只荷瘤鼠随机分为5组，每组12只。种植12d后分别自腹腔内注射生理盐水（对照组）、Endostatin（E组）、SU6668（S组）、Endostatin加SU6668（E加S组）、Endostatin加SU6668加5-FU（E加S加F组），1次／d，共4周。种植后第6周末处死动物，测量原位肿瘤瘤重、抑瘤率和肿瘤微血管密度（MVD），观察肿瘤肝腹膜和区域淋巴结转移及腹水出现情况。结果对照组、E组、S组、E加S组、E加S加F组抑瘤率分别为0、64．9％、63．5％、76．4％和88．2％；MVD分别为（18．10±5．65）、（2．75±0．75）、（3．17±0．58）、（0．94±0．42）和（0．36±0．45）；腹膜转移率分别为90％、16．7％、25％、0和0；区域淋巴结转移率分别为90％、0、0、0和0。E组、S组、E加S组、E加S加F组与对照组相比，结肠癌生长和转移受到明显抑制（P〈0．05）；尤以E加S加F组明显（P〈0．01）。结论Endostatin和SU6668联合5-FU具有协同作用，能更有效地抑制结肠癌的生长和转移。